Conversely, both Norton and colleagues and Feng and colleagues showed that mice with Vps34-deficient Tregs have enhanced antitumor immunity [3,7], suggesting that pharmaceutical inhibition of Vps34 could improve cancer treatment. The gene discussed is PIK3C3; the disease is cancer.